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We report here on a quantitative real-time reverse transcription-PCR (qRT-PCR) assay for assessing drug
efficacy against the intracellular pathogen Cryptosporidium parvum. The qRT-PCR assay detects 18S rRNA
transcripts from both parasites, that is, the cycle threshold for 18S rRNA from parasites (CT[P18S]) and host
cells (CT[H18S]), and evaluates the relative expression between parasite and host rRNA levels (i.e., CT 
CT[P18S]  CT[H18S]) to minimize experimental and operational errors. The choice of qRT-PCR over quanti-
tative PCR (qPCR) in this study is based on the observations that (i) the relationship between the logarithm
of infected parasites (log[P]) and the normalized relative level of rRNA (CT) is linear, with a fourfold
dynamic range, by qRT-PCR but sigmoidal (nonlinear) by qPCR; and (ii) the level of RNA represents that of
live parasites better than that of DNA, because the decay of RNA (99% in3 h) in dead parasites is faster than
that of DNA (99% in 24 to 48 h) under in vitro conditions. The reliability of the qRT-PCR method was
validated by testing the efficacies of nitazoxanide and paromomycin on the development of two strains of C.
parvum (IOWA and KSU-1) in HCT-8 cells in vitro. Both compounds displayed dose-dependent inhibitions.
The observed MIC50 values for nitazoxanide and paromomycin were 0.30 to 0.45 g/ml and 89.7 to 119.0 g/ml,
respectively, comparable to the values reported previously. Using the qRT-PCR assay, we have also observed
that pyrazole could inhibit C. parvum development in vitro (MIC50  15.8 mM), suggesting that the recently
discovered Cryptosporidium alcohol dehydrogenases may be explored as new drug targets.
Cryptosporidium parvum is an intracellular parasitic protist
that infects both humans and animals (5, 22). This parasite
belongs to the phylum Apicomplexa. However, recent phylo-
genetic reconstructions have suggested that the genus Crypto-
sporidium probably represents an early branch at the base of
the phylum (31). Together with C. hominis (a new species
recently renamed from type 1 C. parvum) (15), C. parvum is
also a significant opportunistic pathogen among immunocom-
promised individuals (e.g., AIDS patients) (5). Currently, only
a single drug (i.e., nitazoxanide [NTZ]) has been approved for
the treatment of cryptosporidiosis in the United States and
Central and South America (10; see also http://www.romark
.com). Therefore, there is a need for the development of new
anti-Cryptosporidium drugs.
In vitro drug testing is a critical step in the early stage of drug
development. To evaluate drug effects against C. parvum in
vitro, parasites must be cultured by infecting human or animal
cells. Currently, several techniques are available for the eval-
uation of drug efficacy against C. parvum in vitro. These tech-
niques include the microscopic method (by counting the num-
ber of fluorescently labeled or chemically stained parasites per
microscopic field) (8), microtiter enzyme-linked immunosor-
bent assay (25, 26), chemiluminescence immunoassay (28, 29),
and potentially real-time quantitative PCR (qPCR) (6, 13).
While all methods may reliably detect the level of parasites in
vitro, many have their own limitations. The microscopic
method can be labor-intensive and highly subjective. Antibody-
based techniques rely on the availability of good antibodies and
are limited by the sensitive and limited signal-to-noise ratio
(25). More recently, a real-time qPCR-based method has been
introduced for assessment of the effects of drugs against C.
parvum in vitro by detecting the level of parasite DNA, and this
method promised a wide dynamic range of detection (6, 13).
However, our recent observations suggest that the DNA level
may not always be well correlated with the number of infected
parasites because the relationship between the inoculated
number of parasites and the normalized cycle thresholds (CTs)
of detection by qPCR is not linear. Furthermore, the DNA
from dead parasites may also exist in these samples (see below
for details). In addition, the reported qPCR method displayed
significant plate-to-plate variations (13), indicating that im-
provements are needed to take full advantage of the real-time
PCR system for drug testing.
Here we report on an improved method for assessment of
drug efficacy against C. parvum infection in vitro, based on the
quantitative real-time reverse transcription-PCR (qRT-PCR)
technique. By detecting the level of 18S rRNA from parasites,
this method is more likely to detect only live parasites that
survive during the drug treatment. The qRT-PCR method also
includes the detection of host cell 18S rRNA as an internal
control, and the parasite level is assessed by the ratio (relative
expression) of parasite and host 18S rRNA levels. The reliabil-
ity of the qRT-PCR assay was validated by assessing the effi-
cacy of NTZ (the only approved anticryptosporidial medicine)
and paromomycin (a well-established reference compound)
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against two distinct strains (IOWA and KSU-1) of C. parvum.
In addition, the newly established qRT-PCR method was also
used to assess the in vitro efficacy of pyrazole, an alcohol
dehydrogenase (ADH) inhibitor, against the growth of C. par-
vum in vitro.
MATERIALS AND METHODS
Parasite cultivation. Only C. parvum oocysts (IOWA and KSU-1 strains) less
than 3 months old (since the time of harvest from infected calves) were used in
all experiments. Oocysts were purified by Percoll gradient centrifugation and
bleached briefly as described previously (16, 30). HCT-8 cells (2.5  105/well)
were seeded in 24-well plates and allowed to grow overnight or until they reached
80% confluence at 37°C with 5% CO2 in RPMI 1640 medium containing 10%
fetal bovine serum, 15 mM HEPES, and other supplements, as described previ-
ously (4, 23). For the generation of standard curves, host cells were infected with
10-fold serial dilutions of parasite oocysts, with host cell-to-parasite ratios rang-
ing from 5:1 to 50,000:1 (i.e., 50,000 to 5 oocysts/well). For drug testing, host cells
were infected with 50,000 oocysts per well. In all experiments, parasites were
allowed to incubate at 3 h at 37°C for excystation and invasion into host cells.
Parasites that failed to invade host cells were removed from the plates by an
exchange of the culture medium. Negative controls that received no parasites
were included in each experiment. To make stock solutions of compounds,
paromomycin or pyrazole (both from Sigma-Aldrich Inc., St. Louis, MO) was
dissolved in water, while NTZ (Sequoia Research Products Ltd., Oxford, United
Kingdom) was dissolved in 1% dimethyl sulfoxide. All compounds were then
added to the infected cells at the specified final concentrations during the me-
dium exchange. Parasite-infected cells were then incubated at 37°C with 5% CO2
for 44 h. At least two wells in different plates were employed for each experi-
mental condition, and all experiments were repeated two or more times.
qRT-PCR and qPCR. Total RNA and genomic DNA (gDNA) were isolated
from parasite-infected cells at 44 h postinfection by using RNeasy and DNeasy
isolation kits (QIAGEN Inc., Valencia, CA), respectively. The concentrations
and the quality of the RNA and the DNA in each sample were determined by
measuring their absorbances at 260 and 280 nm, respectively. All RNA and
gDNA samples were adjusted to a concentration of 20 ng/l. The detection of
parasite 18S rRNA employed a pair of previously published primers (i.e., primers
Cp18S-995F [5-TAG AGA TTG GAG GTT GTT CCT-3] and Cp18S-1206R
[5-CTC CAC CAA CTA AGA ACG GCC-3]) (1, 4). The primers specific to
human 18S rRNA (primers Hs18S-F1373 [5-CCG ATA ACG AAC GAG ACT
CTG G-3] and Hs18S-R1561 [5-TAG GGT AGG CAC ACG CTG AGC C-3])
were designed after comparison of published sequences of the human and Cryp-
tosporidium 18S rRNA genes. The expected sizes of the amplicons obtained by
using these two pairs of primers were 212 bp and 189 bp, respectively. A SYBR
green-based real-time RT-PCR protocol was employed by using an iScript One-
Step RT-PCR kit with SYBR green (Bio-Rad Laboratories, Hercules, CA).
Reaction mixtures containing 20 ng total RNA; and appropriate amounts of
reagents and primers were first incubated at 48°C for 30 min to synthesize cDNA,
heated at 95°C for 15 min to inactivate the reverse transcriptase, and then
subjected to 40 thermal cycles (95°C for 20 s, 50°C for 30 s, and 72°C for 30 s) of
PCR amplification with an iCycler iQ real-time PCR detection system (Bio-Rad
Laboratories). The qPCR analysis was performed similarly with 20 ng gDNA
(IOWA strain only) as the template in each reaction, but reverse transcriptase
and the reverse transcription step were omitted. At least two replicate reactions
were performed for each sample.
Quantitative analysis by qRT-PCR. For each sample, the CTs for detection of
the 18S rRNA levels of parasites (CT[P18S]) and host cells (CT[H18S]) were de-
termined by qRT-PCR. The relative level of parasites in each sample was first
determined by measurement of the ratio between those of parasite and host cells,
i.e., the difference between CT[P18S] and CT[H18S] (CT):
CT CTP18S CTH18S (1)
Next, in each of experiments all CT values (relative levels of C. parvum 18S
rRNA) were further normalized by subtracting from them the mean of the CT
values derived from the samples infected with highest number of parasites (the
set of lowest CT values). This resulted in the normalized relative levels of
parasite 18S rRNA among different samples (CT). For example, in a group of
five samples (infected with 5 to 50,000 oocysts/well) each CT value (represented
by CTn, where n 	 1 to 5) was reduced by the mean of the CT values derived
from samples infected with 50,000 oocysts/well (represented by CT1), as indi-
cated by
CTn CTn CT1 (2)
For the calculation of standard curves, the CT values were plotted against
the logarithm of the number of inoculated parasite oocysts (log[P]). After linear
regression, the following relationship was obtained:
logP A  CT B (3)
where A is the slope of the regression line and B is the intersection and in one
of our standard curves were found to be 0.2961 and 5.037, respectively (Fig. 1A).
To evaluate the efficacies of NTZ, paromomycin, and pyrazole against C. par-
vum, the normalized relative levels of pathogen between experimental samples
(Pexp) (with drug treatment) and controls (Pctl) (without drug treatment) were
determined for computation of the percent inhibition. For this purpose, we first
determined the relationship between the logarithms of Pexp and Pctl:
log
Pexp/Pctl logPexp log[Pctl] A  
CT CT[ctl] (4)
where A represents the slope of the regression line. The resulting equation
(equation 4) indicates that the logarithm of the normalized relative level of
FIG. 1. Standard curves for IOWA strain (A) and KSU-1 strain
(B) of C. parvum infection in HCT-8 cells as determined by qRT-PCR
(solid line) and qPCR (dashed line) by detecting the parasite and host
cell 18S rRNA and 18S rRNA gene. At each oocyst inoculum level, the
mean CT values were derived from two sample replicates, and each
sample was subjected to at least two qRT-PCRs or qPCRs. The qRT-
PCR curve was derived by a linear regression between the CT values
and the logarithm of oocyst inoculum (presented here as the number
of oocysts per 106 host cells), whereas the qPCR curve was derived by
a nonlinear regression by using a four-parameter logistic equation (see
equation 9 in Materials and Methods). Bars represent standard errors
of the means.
4438 CAI ET AL. ANTIMICROB. AGENTS CHEMOTHER.
 o
n
 Septem
ber 11, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
pathogen between two experimental samples is defined only by the slope (value
A) and CT. The intersection (value B) is not needed to calculate percent
inhibition. Because all samples were normalized against uninfected controls,
CT[ctl] would equal zero and the previous equation (equation 4) could be
simplified to
log(Pexp/Pctl)  A  CT (5)
From equation 5, the relative level of parasites between experimental and
control samples were calculated as follows:
Pexp/Pctl 10A  CT (6)
Pexp/Pctl εCT (7)
The parameter ε is commonly referred to as the amplification efficiency, which
should normally range between 1 (no amplification) and 2 (100% amplification
efficiency) (24). However, one must distinguish the ε value from the “percent
PCR efficiency” calculated directly by the programs implemented in some real-
time PCR systems, which may actually equal (ε –1) · 100.
The inhibition curves derived from equation 6 or 7 were subject to nonlinear
regression (curve fit) against log-transformed drug concentrations by using the
Prism v4.0 program (GraphPad Software, San Diego, CA). The MIC50 for each
compound was typically derived from the sigmoidal model by determining the
drug concentrations that caused a 50% reduction of parasite growth in compar-
ison to the growth of the controls. In addition, percent inhibition curves com-
monly used for the presentation of drug inhibition data could also be computed
by using following equation:
% inhibition  [1  (Pexp/Pctl)]  (100%)  (1  10ACT)  (100)
(8)
Nonlinear regression analysis and computation of the MIC50 may also be
performed for the data sets derived by using equation 8 by using an appropriate
curve-fitting model. For computation of standard errors (SEs), the mean of the
normalized value in all control samples (i.e., CT[ctl]) was calculated first for
each set of experiments (e.g., all data derived from the one plate) as a normal-
ization baseline. The percent inhibition and SE values of all samples (including
those of the controls) can then be calculated individually from the normalized
CT values.
Quantitative analysis by qPCR. The qPCR analysis was performed only for
samples infected with various numbers of the IOWA parasite strain. Similar to
qRT-PCR analysis, the CT values were calculated for each set of experiments.
However, we determined that for qPCR, the relationship between the CT
values and the logarithm of infected parasites (i.e., oocyst numbers) was sigmoi-
dal rather than linear. Therefore, only nonlinear regressions of qPCR data were
performed to generate best-fit sigmoidal curves by using the Prism v4.0 program
with the following four-parameter logistic equation:
Y bottom 
top bottom/
1 10
logEC50  X  h (9)
For the reasons discussed below, the qPCR method was not used for assess-
ment of the efficacies of NTZ, paromomycin, or pyrazole against C. parvum
growth in vitro.
Decay of RNA and DNA from dead C. parvum sporozoites. To test how long
the RNA and DNA in dead parasites could exist in the current in vitro system,
we prepared free sporozoites (IOWA strain) by excystation of fresh oocysts and
inactivated them by three cycles of freezing (80°C for 1 h) and thawing (room
temperature for 30 min). HCT-8 cells were cultured in 24-well plates as de-
scribed above. Dead sporozoites (200,000 per well) were added to the cultured
HCT-8 cells by a medium change and incubated at 37°C for 1, 3, 6, 16, and 48 h.
Each experimental condition included at least two replicates. At each specified
time point, the supernatant in each well was collected and centrifuged, and the
pellet was combined with its corresponding monolayer for the isolation of total
RNA and gDNA for qRT-PCR and qPCR analyses. In both analyses, the CT
values were calculated and the relative amount of detectable parasite 18S rRNA
and 18S rRNA gene were computed according to their corresponding standard
curves.
RESULTS
Comparison of qRT-PCR and qPCR assays. In this study, we
chose to derive standard curves from samples infected with a
serially diluted numbers of parasites rather than from serially
diluted, purified RNA or DNA. Therefore, the relationship
between CT and normalized levels of parasite 18S rRNA
that were determined should truly reflect the level of parasites.
The two sets of primers employed in this study were specific to
their corresponding templates, as no detectable nonspecific
products were observed by melting curve analysis or agarose
gel electrophoresis of their amplicons (data not shown). We
first tested the linearity of the data generated by qRT-PCR
(IOWA and KSU-1 strains) and qPCR (IOWA strain) in sam-
ples infected with 5 to 50,000 oocysts (per 250,000 HCT-8
cells). We observed that the relationships between normalized
CT values and the parasite levels (in a wide range of 4
orders of magnitude) were highly linear in the qRT-PCR assay
for both the IOWA and the KSU-1 strains (Fig. 1A and B) but
were apparently nonlinear (sigmoidal) in the qPCR assay (Fig.
1A).
Although nonlinear regression could generate a well-fit sig-
moidal curve for the qPCR data (R2 	 0.9926) for calculation
of the parasite level in experimental samples (IOWA strain)
(Fig. 1A, dashed line), the computation would be more com-
plicated than the use of the linear standard curve produced by
qRT-PCR (Fig. 1A and B, solid lines). The mechanism behind
the unexpected sigmoidal relationship between CT and the
number of infected C. parvum oocysts in the qPCR assay was
unclear. Similar nonlinearity in a qPCR assay was recently
observed in a study where 5 to 250 oocysts were infected per
well in 96-well microplates (i.e., 2 orders of magnitude),
although linearity was apparent among samples infected with
5, 25, and 50 oocysts (i.e., within 1 order of magnitude) (see
Fig. 2 in reference 6). Since the qPCR assay detects the level of
the 18S rRNA gene and since DNA replication is associated
with the parasite cell cycle, we speculate that the rate of DNA
replication in cultured C. parvum cells may vary slightly de-
pending on the density of parasites (i.e., faster cell cycles in
samples with host cell:oocyst inoculum ratios ranging from
50:1 to 500:1) (Fig. 1A, points marked with asterisks).
The advantage of using qRT-PCR to quantify the growth of
C. parvum in vitro is further supported by the RNA and DNA
decay data determined by qRT-PCR and qPCR, respectively
(Fig. 2). In this experiment, 99% of RNA in dead sporozoites
(IOWA strain) decayed within 3 h under current cell culture
conditions. However, only 56% and 87% of DNA in dead
sporozoites decayed by 3 and 6 h, respectively, and 3.5% of
the DNA remained in the culture for up to 16 h under the same
conditions (Fig. 2B). These results suggest that DNA may
remain in the culture for a longer period of time than RNA
after the parasites are killed by drugs and strongly indicate that
qRT-PCR is more likely to detect viable parasites than the
qPCR assay. In other words, qPCR may overestimate the par-
asite level (and thus underestimate drug efficacy) if a com-
pound under investigation kills cultured Cryptosporidium cells
in the later stages of the parasite life cycle, because a signifi-
cant amount of DNA from these dead parasites may persist for
up to 16 h in the system.
Drug testing in vitro. We first validated the reliability of the
qRT-PCR assay by examining the efficacies of NTZ and paro-
momycin in reducing the growth of two strains of C. parvum
(IOWA and KSU-1) in vitro. NTZ is the only drug approved
for use for the treatment of cryptosporidiosis, while paromo-
mycin is a well established “gold standard” in drug testing
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against C. parvum (11, 14, 18–20, 25, 28). In this test, both NTZ
and paromomycin displayed dose-dependent inhibition of the
IOWA and the KSU-1 strains of C. parvum cultured with
HCT-8 cells (Fig. 3). The inhibition curves were well fit, as
determined by nonlinear regressions. The MIC50 values for
NTZ required to inhibit the IOWA and the KSU-1 strains
were determined to be 0.30 and 0.45 g/ml, respectively (Fig.
3A), which are slightly lower but comparable to the previously
published value of 1.2 g/ml (12). The growth of C. parvum in
vitro was almost completely inhibited by NTZ at concentra-
tions of 12.5 g/ml or higher. The MIC50 values for paromo-
mycin to inhibit the IOWA and the KSU-1 strains were deter-
mined to be 89.7 and 119.0 g/ml, respectively, which is
comparable to the published values determined by in situ en-
zyme-linked immunosorbent assay (25, 26), chemilumines-
cence immunoassay (28, 29), and microscopic methods (18).
The maximum inhibition reached 95% when paromomycin
was used at a concentration of 810 g/ml, which also agrees
well with previously reported data.
Second, we employed the qRT-PCR assay to evaluate the
efficacy of pyrazole on the growth of C. parvum in vitro. Pyra-
zole is an inhibitor of ADH (3, 7, 9, 17, 21). Recently, two
distinct ADH genes (CpADH1 and CpADH-E) have been dis-
covered from the C. parvum and the C. hominis genomes (2).
Therefore, testing of the efficacy of pyrazole has the potential
for evaluation of whether these two ADH enzymes may be
explored as novel drug targets against Cryptosporidium (2, 27).
At concentrations ranging from 3.1 to 50 mM, pyrazole dis-
played a dose-dependent inhibition of the growth of C. parvum
(IOWA strain) in vitro (R2 	 0.9215) (Fig. 4A). The MIC50
determined by nonlinear curve regression was 15.8 mM, and a
maximum inhibition of 93.4% was observed at a concentration
of 50 mM. No significant cytotoxicity to HCT-8 cells was ob-
served (by t test, P 	 0.001) for pyrazole at any of the concen-
trations tested except the highest concentration (50 mM), in
which a 28% reduction in enzyme activity was observed by the
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium
bromide) assay (Fig. 4B). These observations suggest that
pyrazole and analogs, as well as other ADH inhibitors, may be
explored as potential drugs for the control of C. parvum infec-
tion.
DISCUSSION
We have established a qRT-PCR assay for the assessment of
drug efficacy against C. parvum in vitro. By this method, the
level of parasite 18S rRNA detected by qRT-PCR was used as
an indicator of the parasite level in drug-treated samples. The
FIG. 2. Decay of RNA and DNA in dead C. parvum sporozoites
spiked into the HCT-8 cells in 24-well plates. After incubation at 37°C
for the specified periods of time, total RNA and DNA were isolated
for the detection of parasite and host cell 18S rRNA and the 18S
rRNA gene by qRT-PCR and qPCR, respectively. The mean of the
CT values at each time point of incubation was derived from at least
two sample replicates, and each sample was subjected to at least two
qRT-PCRs or qPCRs. (A) The CT values required for detection of
parasite 18S rRNA (solid line) or the 18S rRNA gene (dashed line);
(B) the percent decay of parasite RNA and DNA derived from the
CT values by using the standard curves shown in Fig. 1. Bars rep-
resent standard errors of the means.
FIG. 3. Efficacies of nitazoxanide (A) and paromomycin (B) on the
growth of C. parvum (IOWA and KSU-1 strains) in vitro, as deter-
mined by the qRT-PCR assay. The percent inhibition curves were
derived by a nonlinear regression by using a hyperbolic equation (A) or
sigmoidal model (B). Bars represent standard errors of the means
derived from at least four replicates.
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level of parasite 18S rRNA was normalized by using that of the
host cell 18S rRNA for each experimental condition. The re-
liability of the qRT-PCR assay was validated by testing the
efficacies of NTZ and paromomycin as reference compounds.
The observed MIC50 values for both compounds were compa-
rable to the previously published ones.
Using the qRT-PCR assay, we also observed that pyrazole
could inhibit the growth of C. parvum in vitro in a dose-
dependent manner, which suggests that CpADH1 and
CpADH-E may be explored as novel targets for drug develop-
ment. However, our data on the efficacy of pyrazole is limited
only to the in vitro model of C. parvum infection. Further
studies with appropriate in vivo models of cryptosporidiosis are
needed to confirm whether pyrazole and analogs may be truly
developed into new anticryptosporidial drugs.
Because of the high sensitivity of the real-time PCR tech-
nology, it is critical to accurately add the same amount of RNA
in all reactions. However, errors may easily be introduced in
this step, either by pipetting errors during the manipulation of
a large number of samples or because the RNA concentrations
in the original samples cannot be accurately determined (e.g.,
contamination with minor amounts of protein, DNA, or other
molecules is one of the possible common causes). The purpose
of detecting the levels of both parasite and host cell 18S rRNA
from the same samples and using host cell 18S rRNA as a
reference control for normalization is to minimize these errors.
In this study, the variations among plates and different exper-
iments were greatly minimized in the qRT-PCR assay, as
shown by both the SE of each experimental condition and the
R2 values (0.9893 and 0.9482 for the IOWA and the KSU-1
strains, respectively) of the standard curve (Fig. 1). Variations
were higher when the thresholds for the detection of parasite
18S rRNA were not normalized by host 18S rRNA (data not
shown), suggesting that the use of host RNA as a reference was
a valid approach for the qRT-PCR (or qPCR, when applica-
ble) detection of intracellular pathogens.
The present qRT-PCR assay is based on a SYBR green
detection format, which is more economical than other detec-
tion methods and which can easily be adopted by other labo-
ratories. However, it requires separate amplifications of para-
site and host rRNA for each sample, and the normalization by
using the host rRNA levels may not correct the potential pi-
petting errors introduced in this step (although it can be
greatly minimized by careful operation). Therefore, there are
potentials to further optimize the present qRT-PCR method
by detecting both pathogen and host rRNA together in a single
reaction by using a probe-based real-time RT-PCR, albeit with
higher costs and the optimization of additional parameters.
The establishment of a qRT-PCR assay provides an alter-
native method to the currently available techniques for the
evaluation of drug efficacy against Cryptosporidium in vitro.
The algorithms provided and the concept of using the patho-
gen-to-host cell ratio for quantitative analysis may also be
employed for screening for the effects of drug against other
intracellular pathogens, including parasites, bacteria, and vi-
ruses. Because automated operation platforms are already
available for cell culture, the isolation of nucleic acids, and the
operation of PCR machines, this qRT-PCR method may po-
tentially be adopted for high-throughput screening of the ef-
fects of drugs against Cryptosporidium.
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